Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

International Team Tracks Clues To HIV
Rice University"s Andrew Barron and his group, working with labs in Italy, Germany and Greece, have identified specific molecules that could block the means by which the deadly virus spreads by taking away its ability to bind with other proteins.

Function Of Key Protein In Cancer Spread Described By LSUHSC Researchers
Research led by David Worthylake, PhD, Assistant Professor of Biochemistry and Molecular Biology at LSU Health Sciences Center New Orleans, may help lay the groundwork for the development of a compound to prevent the spread of cancer. The research will be published in the May 29, 2009 issue of the Journal of Biological Chemistry.
News of the day
Advocacy Group, N.D. Abortion Clinic File Lawsuit To Block State Ultrasound Law
The Red River Women"s Clinic in Fargo, N.D., went to court on Thursday to block a state law from going into effect that would require the clinic to give women the option to view ultrasound images and hear a fetal heartbeat 24 hours before receiving abortion services, the AP/Bismarck Tribune reports. The suit was filed in East Central District Court by the Center for Reproductive Rights on behalf of the clinic, which is the only abortion clinic in North Dakota. In the lawsuit, the clinic asked the court to issue a temporary injunction to prevent the law from taking effect on Aug. 1. A hearing has been scheduled for July 30.Suzanne Stolz, an attorney for CRR, said the law is "unconstitutional"” because it "creates an undue burden on a woman"s right to have an abortion." In a statement, CRR said that the law requires an audible fetal heartbeat consistent with "standard medical practice in the community." However, the Center said no such standard exists. In addition, Stolz said that the North Dakota law is less clear than laws in other states with ultrasound mandates that include a fetal heartbeat provision, including Georgia, Indiana, Kansas, Mississippi, Oklahoma and Wisconsin. Furthermore, CRR said that the equipment needed to provide the audible heartbeat would be expensive for the clinic, although it did not say what the cost would be.Tammi Kromenaker, director of the clinic, said it has offered women the option of viewing an ultrasound image since 2008. She said that the issue with the law is that it is not clear about whether a woman who chooses to view the image must also listen to the fetal heartbeat -- which sometimes cannot be heard in the early stages of pregnancy -- and about the level of technology the clinic must provide.Mary Spaulding Balch, a spokesperson for the National Right to Life Committee, said that the law is not burdensome to women seeking abortions and that it would only require the clinic to use "a simple device used by obstetrician[s] that amplifies" a fetal heartbeat. State Rep. Bette Grande (R), a sponsor of the law, said that the law does not require the Red River clinic to perform the ultrasound. She added that a woman seeking an abortion could receive the image and audio from another clinic prior to the procedure. Grande also noted that the law does not require women to view the ultrasound image and hear the fetal heartbeat -- it "just says they will have this opportunity" (MacPherson, AP/Bismarck Tribune, 7/24).
Medical Devices

UCB And Biogen Idec Discontinue Phase II Clinical Trial Of CDP323

UCB and Biogen Idec announced the discontinuation of the Phase II clinical trial of CDP323 for the treatment of relapsing multiple sclerosis (MS). Preliminary interim efficacy analysis showed that patients enrolled in this clinical trial did not benefit as expected from CDP323 compared to placebo after a six month treatment period. No cases of PML (progressive multifocal leukoencephalopathy) were noted. CDP323 is an oral small molecule alpha4 integrin inhibitor that was being developed by UCB and Biogen Idec for relapsing forms of multiple sclerosis. For UCB, results of this interim analysis trigger a re-valuation of the intangible asset "CDP323". UCB expects a non-cash, non-recurring impairment of a high double-digit million pre-tax euro amount. This will be more than compensated by cash, non-recurring capital gains, which resulted from the divestitures UCB made earlier this year. More information on the financial impacts of both the impairment and the capital gains will be included in the Half Year Report 2009 of UCB, due July 31, 2009. About Multiple Sclerosis Multiple sclerosis (MS) is a chronic disease of the central nervous system that affects an estimated 1.1 - 2.5 million people worldwide. Although the exact cause is unknown, MS occurs as a result of loss of the protective outer coating on nerves in the brain and spinal cord. Deterioration in the way that messages are transmitted around the body leads to loss of movement and other body functions. Symptoms of MS can include vision problems, loss of balance, numbness, difficulty walking and paralysis. About Biogen Idec Biogen Idec creates new standards of care in therapeutic areas with high unmet medical needs. Founded in 1978, Biogen Idec is a global leader in the discovery, development, manufacturing, and commercialization of innovative therapies. Patients in more than 90 countries benefit from Biogen Idec"s significant products that address diseases such as lymphoma, multiple sclerosis, and rheumatoid arthritis. For product labeling, press releases and additional information about the company, please visit http://www.biogenidec.com. UCB


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009